Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study
ObjectiveThe aim of the current study was to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) in elderly patients diagnosed as advanced hepatocellular carcinoma (HCC) accompanied with different types of portal vein tumor thrombosis (PVTT).MethodsElderly HCC patient...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.646410/full |
| _version_ | 1818438426299465728 |
|---|---|
| author | Qinghe Tang Wei Huang Jun Liang Jun Liang Junli Xue |
| author_facet | Qinghe Tang Wei Huang Jun Liang Jun Liang Junli Xue |
| author_sort | Qinghe Tang |
| collection | DOAJ |
| description | ObjectiveThe aim of the current study was to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) in elderly patients diagnosed as advanced hepatocellular carcinoma (HCC) accompanied with different types of portal vein tumor thrombosis (PVTT).MethodsElderly HCC patients aged 70-year-old and above from January 2015 to December 2019 were included in this retrospective study. Efficacy data including OS, PFS, DCR, and ORR and safety data were collected in the indicated groups. Outcomes of HCC patients in the TACE group were compared with those patients in the best supportive care (BSC) group. Subgroup analyses were also conducted in the patients with different types of PVTT.ResultsAmong 245 elderly HCC patients, 124 were enrolled in this study. Out of these, 50.0% (n=62) underwent BSC treatment while 50.0% (n=62) underwent TACE. There were no major differences in the baseline characteristics of the two treatment groups. TACE treatment was associated with better median OS compared with BSC alone (11.30 m vs. 7.80 m; P<0.001). Subgroup analyses showed that patients with type I and type II PVTT could benefit from TACE compared with BSC, based on that OS was 14.30 m vs. 7.80 m (P=0.007) and 13.00 m vs. 8.00 m (P=0.002), respectively. The DCR in the TACE group was 62.90%, and 17.74% in the BSC group (p<0.001). The proportion of ORR in TACE group was 35.48%, while 0.00% in the BSC group (p<0.001). Multivariable analyses showed that patients undergoing TACE treatment had 52% lower odds of mortality compared with patients undergoing BSC treatment (HR: 0.48; 95%CI: 0.32-0.72). Similarly, the media PFS was improved following TACE treatment (7.50 m vs. 4.00 m; P<0.001). TACE could significantly prolong the PFS in both type I and type II PVTT subgroups, without greatly significant improvement in type III PVTT patients (4.50 m vs. 2.70 m; P=0.103). Type III PVTT patients in the TACE group had more AEs than type I and type II PVTT patients. According to multivariable analyses, PVTT types (type III vs. type I-II) (HR: 2.18; 95%CI: 1.29-3.70; P=0.004), tumor diameter (>5 cm vs. ≤5 cm) (HR: 1.94; 95%CI: 1.28-2.93; P=0.002), and treatment (TACE vs. BSC) (HR: 0.48; 95%CI: 0.32-0.72; P<0.001) were independent indicators of overall survival.ConclusionsIn elderly advanced HCC patients with PVTT, palliative TACE treatment can be an accessible effective measure to improve the OS and PFS for both type I and type II PVTT patients. |
| first_indexed | 2024-12-14T17:40:23Z |
| format | Article |
| id | doaj.art-d40e80e0a58640e4a78e7909582a8496 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T17:40:23Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d40e80e0a58640e4a78e7909582a84962022-12-21T22:52:52ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-07-011110.3389/fonc.2021.646410646410Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective StudyQinghe Tang0Wei Huang1Jun Liang2Jun Liang3Junli Xue4Department of Hepatobiliary and Pancreatic Surgery Department, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Hepatobiliary and Pancreatic Surgery Department, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Intervention Therapy, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, ChinaDepartment of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, ChinaObjectiveThe aim of the current study was to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) in elderly patients diagnosed as advanced hepatocellular carcinoma (HCC) accompanied with different types of portal vein tumor thrombosis (PVTT).MethodsElderly HCC patients aged 70-year-old and above from January 2015 to December 2019 were included in this retrospective study. Efficacy data including OS, PFS, DCR, and ORR and safety data were collected in the indicated groups. Outcomes of HCC patients in the TACE group were compared with those patients in the best supportive care (BSC) group. Subgroup analyses were also conducted in the patients with different types of PVTT.ResultsAmong 245 elderly HCC patients, 124 were enrolled in this study. Out of these, 50.0% (n=62) underwent BSC treatment while 50.0% (n=62) underwent TACE. There were no major differences in the baseline characteristics of the two treatment groups. TACE treatment was associated with better median OS compared with BSC alone (11.30 m vs. 7.80 m; P<0.001). Subgroup analyses showed that patients with type I and type II PVTT could benefit from TACE compared with BSC, based on that OS was 14.30 m vs. 7.80 m (P=0.007) and 13.00 m vs. 8.00 m (P=0.002), respectively. The DCR in the TACE group was 62.90%, and 17.74% in the BSC group (p<0.001). The proportion of ORR in TACE group was 35.48%, while 0.00% in the BSC group (p<0.001). Multivariable analyses showed that patients undergoing TACE treatment had 52% lower odds of mortality compared with patients undergoing BSC treatment (HR: 0.48; 95%CI: 0.32-0.72). Similarly, the media PFS was improved following TACE treatment (7.50 m vs. 4.00 m; P<0.001). TACE could significantly prolong the PFS in both type I and type II PVTT subgroups, without greatly significant improvement in type III PVTT patients (4.50 m vs. 2.70 m; P=0.103). Type III PVTT patients in the TACE group had more AEs than type I and type II PVTT patients. According to multivariable analyses, PVTT types (type III vs. type I-II) (HR: 2.18; 95%CI: 1.29-3.70; P=0.004), tumor diameter (>5 cm vs. ≤5 cm) (HR: 1.94; 95%CI: 1.28-2.93; P=0.002), and treatment (TACE vs. BSC) (HR: 0.48; 95%CI: 0.32-0.72; P<0.001) were independent indicators of overall survival.ConclusionsIn elderly advanced HCC patients with PVTT, palliative TACE treatment can be an accessible effective measure to improve the OS and PFS for both type I and type II PVTT patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.646410/fullTACEelderly patientsadvanced HCCPVTTadverse event |
| spellingShingle | Qinghe Tang Wei Huang Jun Liang Jun Liang Junli Xue Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study Frontiers in Oncology TACE elderly patients advanced HCC PVTT adverse event |
| title | Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study |
| title_full | Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study |
| title_fullStr | Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study |
| title_full_unstemmed | Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study |
| title_short | Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study |
| title_sort | efficacy and safety of transarterial chemoembolization in elderly patients of advanced hepatocellular carcinoma with portal vein tumor thrombus a retrospective study |
| topic | TACE elderly patients advanced HCC PVTT adverse event |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.646410/full |
| work_keys_str_mv | AT qinghetang efficacyandsafetyoftransarterialchemoembolizationinelderlypatientsofadvancedhepatocellularcarcinomawithportalveintumorthrombusaretrospectivestudy AT weihuang efficacyandsafetyoftransarterialchemoembolizationinelderlypatientsofadvancedhepatocellularcarcinomawithportalveintumorthrombusaretrospectivestudy AT junliang efficacyandsafetyoftransarterialchemoembolizationinelderlypatientsofadvancedhepatocellularcarcinomawithportalveintumorthrombusaretrospectivestudy AT junliang efficacyandsafetyoftransarterialchemoembolizationinelderlypatientsofadvancedhepatocellularcarcinomawithportalveintumorthrombusaretrospectivestudy AT junlixue efficacyandsafetyoftransarterialchemoembolizationinelderlypatientsofadvancedhepatocellularcarcinomawithportalveintumorthrombusaretrospectivestudy |